ZURA
Zura Bio Ltd
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Zura Bio Ltd
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No other changes.
No other changes.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Zura Bio Limited is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and Torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.
Zura Bio Limited is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and Torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.
No thesis.
Annual filing, covered
10-K parsed · Mar 19 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 19 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
| Manager | Value | % base | |
|---|---|---|---|
| Suvretta | $55.7M | 12.95% | +4.15% |
| VR Adviser | $38.0M | 8.83% | 0.00% |
| MPM Oncology Impact | $26.4M | 6.14% | new |
| Great Point Partners | $24.9M | 5.78% | 0.00% |
| JPMorgan Chase | $24.5M | 5.70% | −2.34% |
| Manager | Value | % base | |
|---|---|---|---|
| Suvretta | $55.7M | 12.95% | +4.15% |
| VR Adviser | $38.0M | 8.83% | 0.00% |
| MPM Oncology Impact | $26.4M | 6.14% | new |
| Great Point Partners | $24.9M | 5.78% | 0.00% |
| JPMorgan Chase | $24.5M | 5.70% | −2.34% |
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Zura Bio Ltd.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Zura Bio Ltd.
Bull2
Bear1
Linked news
Zura Bio Ltd
4.00
+0.01 · +0.37%
Expected move
No implied move.